NasdaqGM:HBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. More Details


Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has Harvard Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.3%

HBIO

1.5%

US Life Sciences

-1.1%

US Market


1 Year Return

17.7%

HBIO

46.2%

US Life Sciences

15.0%

US Market

Return vs Industry: HBIO underperformed the US Life Sciences industry which returned 46.2% over the past year.

Return vs Market: HBIO exceeded the US Market which returned 15.6% over the past year.


Shareholder returns

HBIOIndustryMarket
7 Day3.3%1.5%-1.1%
30 Day4.7%9.9%2.9%
90 Day-1.6%9.9%5.7%
1 Year17.7%17.7%46.5%46.2%17.6%15.0%
3 Year-9.3%-9.3%96.6%95.3%38.9%29.7%
5 Year-0.9%-0.9%194.7%190.8%78.4%58.4%

Price Volatility Vs. Market

How volatile is Harvard Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Harvard Bioscience undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HBIO ($3.13) is trading below our estimate of fair value ($14.03)

Significantly Below Fair Value: HBIO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HBIO is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: HBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HBIO is good value based on its PB Ratio (1.6x) compared to the US Life Sciences industry average (6.8x).


Next Steps

Future Growth

How is Harvard Bioscience forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

48.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HBIO's revenue (0.6% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: HBIO's revenue (0.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HBIO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Harvard Bioscience performed over the past 5 years?

22.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HBIO is currently unprofitable.

Growing Profit Margin: HBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 22.3% per year.

Accelerating Growth: Unable to compare HBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (17%).


Return on Equity

High ROE: HBIO has a negative Return on Equity (-10.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Harvard Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: HBIO's short term assets ($44.1M) exceed its short term liabilities ($22.7M).

Long Term Liabilities: HBIO's short term assets ($44.1M) do not cover its long term liabilities ($52.0M).


Debt to Equity History and Analysis

Debt Level: HBIO's debt to equity ratio (58.4%) is considered high.

Reducing Debt: HBIO's debt to equity ratio has increased from 21.8% to 58.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable HBIO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: HBIO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.7% per year.


Next Steps

Dividend

What is Harvard Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jim Green (62 yo)

1.25yrs

Tenure

US$2,708,571

Compensation

Mr. James W. Green, also known as Jim, has been Chairman of Harvard Bioscience, Inc. since June 5, 2017 and has been its Independent Director since April 30, 2015. He serves as President and Chief Executiv ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD2.71M) is above average for companies of similar size in the US market ($USD585.94K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James Green
President1.25yrsUS$2.71m1.49%
$ 1.8m
Michael Rossi
Chief Financial Officer1.25yrsUS$495.03k0.044%
$ 53.5k
Kenneth Olson
Senior Vice President of Global Operations & Engineering0.42yrno datano data
David Sirois
Director of Corporate Accounting & SEC Reportingno datano datano data

1.3yrs

Average Tenure

58yo

Average Age

Experienced Management: HBIO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
James Green
President1.25yrsUS$2.71m1.49%
$ 1.8m
John Kennedy
Independent Director20yrsUS$149.18k0.75%
$ 915.6k
Alan Edrick
Independent Director1.08yrsUS$147.45k0.15%
$ 186.7k
Bertrand Loy
Lead Independent Director1.25yrsUS$152.13k0.71%
$ 866.4k
Thomas Loewald
Independent Director3yrsUS$136.50k0.28%
$ 339.2k
Katherine Eade
Independent Director3yrsUS$132.96k0.32%
$ 395.4k
Susan Steele
Independent Director0.50yrno data0.0079%
$ 9.6k

3.0yrs

Average Tenure

56yo

Average Age

Experienced Board: HBIO's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Harvard Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Harvard Bioscience, Inc.
  • Ticker: HBIO
  • Exchange: NasdaqGM
  • Founded: 1901
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$121.891m
  • Shares outstanding: 38.94m
  • Website: https://www.harvardbioscience.com

Number of Employees


Location

  • Harvard Bioscience, Inc.
  • 84 October Hill Road
  • Suite 10
  • Holliston
  • Massachusetts
  • 1746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HBIONasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2000
HBIDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2000

Biography

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. The company offe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 00:26
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.